Dofetilide: a new class III antiarrhythmic agent

References

• Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Mahe I, Bergmann JF. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch. Intern. Med.166, 719–728 (2006).
   PubMed Web of Science ®Google Scholar
• Echt DS, Liebson PR, Mitchell LB et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N. Engl. J. Med.324, 781–788 (1991).
   PubMed Web of Science ®Google Scholar
• Effect of the antiarrythmic agent moricizine on survival after myocardial infarction.The Cardiac Arrhythmia Supression Trial II investigators. N. Engl. J. Med.327, 227–233 (1992).
   PubMed Web of Science ®Google Scholar
• Waldo AL, Camm AJ, deRuyter H et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet 348, 7–12 (1996).
   PubMed Web of Science ®Google Scholar
• Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 82, 1106–1116 (1990).
   PubMed Web of Science ®Google Scholar
• Geraets DR, Kienzle MG. Atrial fibrillation and atrial flutter. Clin.Pharm.12, 721–735 (1993).
   Google Scholar
• Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 350, 1417–1424 (1997).
   PubMed Web of Science ®Google Scholar
• Gwilt M, Arrowsmith JE, Blackburn KJ et al. UK-68,798: a novel, potent and highly selective class III antiarrhythmic agent which blocks potassium channels in cardiac cells. J. Pharmacol. Exp. Ther.256, 318–324 (1991).
   PubMed Web of Science ®Google Scholar
• Pfizer. . March 2004.
   Google Scholar
• Sedgwick ML, Rasmussen HS, Cobbe SM. Clinical and electrophysiologic effects of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with angina pectoris. Am. J. Cardiol.69, 513–517 (1992).
   PubMed Web of Science ®Google Scholar
• Baskin EP, Lynch JJ, Jr. Differential atrial versus ventricular activities of class III potassium channel blockers. J. Pharmacol. Exp. Ther.285, 135–142 (1998).
   PubMed Web of Science ®Google Scholar
• Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin JP, Pollard CE. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br. J. Pharmacol.142, 1255–1264 (2004).
   Google Scholar
• Demolis JL, Funck-Brentano C, Ropers J, Ghadanfar M, Nichols DJ, Jaillon P. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans. Circulation 94, 1592–1599 (1996).
   PubMed Web of Science ®Google Scholar
• Yang T, Tande PM, Refsum H. Electromechanical action of dofetilide and D-sotalol during simulated metabolic acidosis in isolated guinea pig ventricular muscle. J. Cardiovasc. Pharmacol.20, 889–894 (1992).
   Google Scholar
• Yang T, Tande PM, Lathrop DA, Refsum H. Class III antiarrhythmic action by potassium channel blockade: dofetilide attenuates hypoxia induced electromechanical changes. Cardiovasc.Res.26, 1109–1115 (1992).
   PubMed Web of Science ®Google Scholar
• Kovacs A, Szenasi G. Effects of Dofetilide and EGIS-7229, an Antiarrhythmic Agent Possessing Class III, IV, and IB Activities, on Myocardial Refractoriness in Hyperkalemia, Hypokalemia, and During beta-Adrenergic Activation in the Rabbit Papillary Muscle In Vitro. J. Pharmacol. Sci. 100, 303–309 (2006).
   PubMed Web of Science ®Google Scholar
• Ducroq J, Rouet R, Salle L et al. Class III effects of dofetilide and arrhythmias are modulated by [K+]o in an in vitro model of simulated-ischemia and reperfusion in guinea-pig ventricular myocardium. Eur. J. Pharmacol. 532, 279–289 (2006).
   Google Scholar
• Rouet R, Picard S, Libersa C, Ghandanfar M, Alabaster CT, Gerard JL. Electrophysiological effects of dofetilide in an in vitro model of "border zone" between normal and and ischemic/reperfused myocardium. Circulation 101, 86–93 (2000).
   Google Scholar
• Wallace AA, Stupienski RF, 3rd, Brookes LM, Selnick HG, Claremon DA, Lynch JJ, Jr. Cardiac electrophysiologic and inotropic actions of new and potent methanesulfonanilide class III antiarrhythmic agents in anesthetized dogs. J. Cardiovasc. Pharmacol.18, 687–695 (1991).
   PubMed Web of Science ®Google Scholar
• Rousseau MF, Massart PE, van Eyll C et al. Cardiac and hemodynamic effects of intravenous dofetilide in patients with heart failure. Am. J. Cardiol.87, 1250–1254 (2001).
   Google Scholar
• DeCara JM, Pollak A, Dubrey S, Al E. Positive atrial inotropic effects of dofetilide following cardioversion of atrial fibrillation. J. Am. Coll. Cardiol.31, 432A–433A (19980).
   Google Scholar
• Tham TC, MacLennan BA, Burke MT, Harron DW. Pharmacodynamics and pharmacokinetics of the class III antiarrhythmic agent dofetilide (UK-68,798) in humans. J. Cardiovasc. Pharmacol.21, 507–512 (1993).
   PubMed Web of Science ®Google Scholar
• Gardner MJ, DeMattos SB, Schumacher DA et al. the effect of food on the PK and PD of Dofetilide in healthy male and female subjects [Abstract]. J. Clin. Pharmacol.37, 874 (1997).
   Google Scholar
• Smith DA, Rasmussen HS, Stopher DA, Walker DK. Pharmacokinetics and metabolism of dofetilide in mouse, rat, dog and man. Xenobiotica22, 709–719 (1992).
   PubMed Web of Science ®Google Scholar
• Walker DK, Alabaster CT, Congrave GS et al. Significance of metabolism in the disposition and action of the antidysrhythmic drug, dofetilide. In vitro studies and correlation with in vivo data. Drug. Metab. Dispos.24, 447–455 (1996).
   PubMed Web of Science ®Google Scholar
• Noveck R, Vincent J, Gardner MJ et al. The safety, toleration, PK and PD of dofetilide in patients with hepatic impairment [Abstract]. Br. J. Clin. Pharmacol.38, 170P (1994).
   Google Scholar
• Sedgwick M, Rasmussen HS, Walker D, Cobbe SM. Pharmacokinetic and pharmacodynamic effects of UK-68,798, a new potential class III antiarrhythmic drug. Br. J. Clin. Pharmacol.31, 515–519 (1991).
   Google Scholar
• Nichols DJ, Abel S, Eve MD. The effect of cimetidine (100mg BID and 400mg BID) and ranitidine on the PK and PD of a single dose of dofetilide [Abstract]. J. Clin. Pharmacol.37, 877 (1997).
   Google Scholar
• Kleinermans DF, Nichols DJ, Dalrymple I. Effect of dofetillide on the pharmacokinetics of digoxin. Am. J. Cardiol.87, 248–250 (2001).
   Google Scholar
• Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch. Intern. Med.155, 469–473 (1995).
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke22, 983–988 (1991).
   PubMed Web of Science ®Google Scholar
• Greenbaum RA. Meeting Highlights: Highlights of the 71st scientific sessions of the american heart association. The EMERALD trial. Circulation99, 2486–2491 (1999).
   Google Scholar
• Torp-Pedersen C, Moller M, Bloch-Thomsen PE et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N. Engl. J. Med.341, 857–865 (1999).
   PubMed Web of Science ®Google Scholar
• Kober L, Bloch Thomsen PE, Moller M et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 356, 2052–2058 (2000).
   PubMed Web of Science ®Google Scholar
• Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) substudy. Circulation 104, 292–296 (2001).
   PubMed Web of Science ®Google Scholar
• Singh S, Zoble RG, Yellen L et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102, 2385–2390 (2000).
   PubMed Web of Science ®Google Scholar
• Falk RH, Pollak A, Singh SN, Friedrich T. Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators. J. Am. Coll. Cardiol.29, 385–390 (1997).
   PubMedGoogle Scholar
• Norgaard BL, Wachtell K, Christensen PD et al. Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am. Heart J.137, 1062–1069 (1999).
   PubMed Web of Science ®Google Scholar
• Bianconi L, Castro A, Dinelli M et al. Comparison of intravenously administered dofetilide versus amiodarone in the acute termination of atrial fibrillation and flutter. A multicentre, randomized, double-blind, placebo-controlled study. Eur. Heart J.21, 1265–1273 (2000).
   PubMed Web of Science ®Google Scholar
• Frost L, Mortensen PE, Tingleff J, Platou ES, Christiansen EH, Christiansen N. Efficacy and safety of dofetilide, a new class III antiarrhythmic agent, in acute termination of atrial fibrillation or flutter after coronary artery bypass surgery. Dofetilide Post-CABG Study Group. Int. J. Cardiol. 58, 135–140 (1997).
   PubMed Web of Science ®Google Scholar
• Pfizer. Briefing documents for Tyksin capsules, FDA cardiorenal Divison Advisory Committee. January 1998.
   Google Scholar
• Tendera M, Wnuk-Wojnar AM, Kulakowski P et al. Efficacy and safety of dofetilide in the prevention of symptomatic episodes of paroxysmal supraventricular tachycardia: a 6-month double-blind comparison with propafenone and placebo. Am. Heart J.142, 93–98(2001).
   Google Scholar
• Kobayashi Y, Atarashi H, Ino T et al. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J. Cardiovasc. Pharmacol.30, 367–373 (1997).
   Google Scholar
• Krahn AD, Klein GJ, Yee R. A randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of intravenously administered dofetilide in patients with Wolff-Parkinson-White syndrome. Pacing.Clin. Electrophysiol.24, 1258–1260 (2001).
   PubMed Web of Science ®Google Scholar
• Cobbe SM, Campbell RW, Camm AJ et al. Effects of intravenous dofetilide on induction of atrioventricular re-entrant tachycardia. Heart 86:522–526 (2001).
   Google Scholar
• Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators. N. Engl. J. Med.329, 452–458 (1993).
   PubMed Web of Science ®Google Scholar
• Bashir Y, Thomsen PE, Kingma JH et al. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am. J. Cardiol.76, 1040–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Echt DS, Lee JT, Murray KT et al. A randomized, double-blind, placebo-controlled, dose-ranging study of dofetilide in patients with inducible sustained ventricular tachyarrhythmias. J. Cardiovasc. Electrophysiol.6, 687–699 (1995).
   PubMed Web of Science ®Google Scholar
• Gremillion ST, Echt DS, Smith NA et al. Beneficial effects of intravenous dofetilide in patients undergoing venricular defribillation testing. Circulation 86(suppl), 1264 (1992).
   Google Scholar
• Davis DR, Beatch GN, Dickenson DR, Tang AS. Dofetilide enhances shock-induced extension of refractoriness and lowers defibrillation threshold. Can. J. Cardiol.15, 193–200 (1999).
   Google Scholar
• Echt DS, Gremillion ST, Lee JT et al. Effects of procainamide and lidocaine on defibrillation energy requirements in patients receiving ICD's. J. Cardiovasc. Electrophysiol.5, 752–760 (1994).
   PubMed Web of Science ®Google Scholar
• Pritchett EL, Wilkinson WE. Effect of dofetilide on survival in patients with supraventricular arrhythmias. Am. Heart J. 138, 994–997 (1999).
   PubMed Web of Science ®Google Scholar
• Brendorp B, Elming H, Jun L et al. Qtc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 103, 1422–1427 (2001).
   PubMed Web of Science ®Google Scholar
• Pratt CM, Camm AJ, Cooper W et al. Mortality in the Survival With ORal D-sotalol (SWORD) trial: why did patients die? Am. J. Cardiol.81, 869–876 (1998).
   PubMed Web of Science ®Google Scholar
• Julian D, Camm A, Frangin G et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT. European Myocardial Infarct Amiodarone Trial Investigators. Lancet 349, 667–674 (1997).
   PubMed Web of Science ®Google Scholar
• Cairns J, Connolly S, Roberts R, Gent M. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. Lancet 349, 675–682 (1997).
   PubMed Web of Science ®Google Scholar
• Karam R. Azimilide dihydrochloride, a novel antiarrhythmic agent. Am. J. Cardiol.81(6A), 40D-46D (1998).
   Google Scholar
• Aimond F. Cellular and in vivo electrophysiological effects of dronedarone in normal and postmyocardial infarcted rats. J. Pharmacol. Exp. Ther.292(1), 415–412 (2000).
   PubMed Web of Science ®Google Scholar
• Reiffel JA. Atypical proarrhythmia with dofetilide: monomorphic VT and exercise-induced torsade de pointes. Pacing and clinical electrophysiology: PACE28, 877–879 (2005).
   Google Scholar
• Fuster V. ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation. J. Am. Coll. Cardiol. 48, e149–246 (2006).
   Web of Science ®Google Scholar